Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Phantom, is this infringing on MRKR IP in any way? Thank You
MANA-677679 (TAA-T) is under investigation for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), ambiguous lineage leukemia or lymphoma, chronic myelogenous leukemia (CML), myelodysplastic syndrome, diffuse intrinsic pontine glioma, medulloblastoma, ependymoma, embryonal tumors, choroid plexus carcinoma, other aggressive CNS malignancies, Ewing sarcoma, Wilms tumor, neuroblastoma, rhabdomyosarcoma, soft tissue sarcomas, osteosarcoma, and adenocarcinoma. The therapy is administered parenterally. It constitutes a tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes which act by targeting cancer cells which express WT1, prame, survivin, and mage-A3 tumor-associated antigens.
https://www.pharmaceutical-technology.com/data-insights/mana-677679-mana-therapeutics-high-grade-glioma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-212114&utm_campaign=recommended-articles